NCT04944017View on ClinicalTrials.gov

Ketamine for the Treatment of Depression in Parkinson's Disease

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

November 23, 2021

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Parkinson's DiseaseDepression
Interventions
DRUG

Ketamine Infusion

Participants will receive 6 infusions of ketamine (0.5 mg/kg IV, up to 60 mg total) , administered over 40 minutes while on continuous cardiac monitoring and oximetry

OTHER

Placebo - Saline Infusion

Participants will receive 6 infusions of saline administered over 40 minutes while on continuous cardiac monitoring and oximetry

Trial Locations (1)

06510

Yale New Haven Hospital, New Haven

All Listed Sponsors
collaborator

Fox (Michael J.) Foundation for Parkinson's Research

UNKNOWN

lead

Yale University

OTHER